Mizuho Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its price target decreased by equities researchers at Mizuho from $32.00 to $30.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho’s price target indicates a potential upside of 386.62% from the company’s current price.

Other equities research analysts have also issued reports about the company. JMP Securities restated a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a research report on Tuesday, April 29th. Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research note on Tuesday, April 8th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Monday, April 28th. Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.50.

Kura Oncology Price Performance

NASDAQ:KURA traded up $0.15 during mid-day trading on Monday, reaching $6.17. 608,321 shares of the stock were exchanged, compared to its average volume of 1,177,547. Kura Oncology has a 1-year low of $5.41 and a 1-year high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average price of $6.42 and a 200 day moving average price of $8.72. The firm has a market capitalization of $533.73 million, a PE ratio of -2.61 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analysts’ expectations of $39.08 million. Research analysts expect that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KURA. State of Wyoming purchased a new stake in Kura Oncology in the first quarter worth about $48,000. Virtus ETF Advisers LLC boosted its stake in shares of Kura Oncology by 71.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after buying an additional 3,061 shares during the last quarter. Pallas Capital Advisors LLC purchased a new stake in Kura Oncology during the first quarter valued at $66,000. Flower City Capital bought a new stake in Kura Oncology during the first quarter valued at approximately $79,000. Finally, Magnetar Financial LLC bought a new position in Kura Oncology in the first quarter worth approximately $79,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.